These are also rare, non-cancerous tumors that can grow on the lining of the lung (pleura). They are different from cancer.
Every report comes from a Lived member, sent anonymously.
Have you had Surgery for Solitary Fibrous Tumors?
A solitary fibrous tumor (SFT) is a rare tumor that grows from connective tissue, the supporting tissue that holds organs and other structures in place. It was first described in the pleura, the thin lining of the lungs and chest cavity, but more than two-thirds of these tumors arise elsewhere, including the coverings of the brain, the head and neck, the abdomen and pelvis, and the trunk or limbs. A tumor once called hemangiopericytoma is now recognized as the same disease. Most SFTs grow slowly, and many cause no symptoms for a long time. About half of those in the chest cause no symptoms, and many are found by chance on an x-ray taken for another reason. When a tumor in the chest becomes large enough to press on the lung, it can cause chest pain, a lasting cough or shortness of breath. SFT sits in an unusual middle ground. Older references often call it noncancerous, and many people are cured by surgery. Specialists now classify it with the soft tissue sarcomas, cancers of connective tissue, because a minority of tumors come back or spread to other organs, sometimes many years later.
The cause of SFT is not known, and no lifestyle habit or exposure has been shown to bring it on. Unlike mesothelioma, a cancer of the same chest lining, it is not caused by asbestos. SFT affects men and women about equally and can appear at any age, though it is most often diagnosed in people in their 50s. Nearly every SFT carries a specific genetic change inside the tumor cells: two genes, NAB2 and STAT6, become fused together, which drives the cells to keep growing. This change develops in the tumor itself. It is not inherited and is not passed on to children.
An SFT usually first appears as a mass on imaging. A CT scan or MRI shows its size, its location and how it relates to nearby organs and blood vessels, which matters for planning surgery. Imaging alone cannot confirm what the mass is, because other tumors, including mesothelioma and other sarcomas, can look similar. The diagnosis is made by examining tissue under a microscope, either from a biopsy or from the tumor after it is removed. A stain that detects the STAT6 protein in the cell nucleus, the visible sign of the NAB2-STAT6 fusion, is highly accurate and has made SFT much easier to recognize. The pathologist also looks at features that help estimate the chance of the tumor spreading later. Scoring systems combine the person's age, the size of the tumor and how many cells are actively dividing (the mitotic count) into a low, intermediate or high risk group. These estimates guide follow-up and decisions about extra treatment, but they are imperfect: tumors judged low risk can still come back.
Surgery to remove the whole tumor is the main treatment for an SFT that has not spread, and complete removal is the factor most closely tied to long-term survival. Many tumors in the chest can be removed through small incisions with a camera-guided technique, while large ones may need open surgery. Because these tumors often have a rich blood supply, large ones need careful planning to limit bleeding. When a tumor comes back in one place, removing it again is often possible and worthwhile. Radiation therapy is usually reserved for situations where surgery could not remove all of the tumor, a second operation is not practical, or the tumor has high-risk features. It can lower the chance of the tumor regrowing in the same spot, though it has not clearly been shown to help people live longer. For SFT that cannot be removed or has spread, treatment aims to control growth. Antiangiogenic drugs, targeted medicines such as pazopanib that block the signals tumors use to build new blood vessels, are often the first choice for the more common, slower-growing forms. They tend to stabilize the tumor for a period of months rather than shrink it much. Chemotherapy is generally less effective for SFT than for other sarcomas, though some combinations, such as dacarbazine with doxorubicin, are preferred for the dedifferentiated form, an aggressive subtype that behaves like a high-grade sarcoma. None of these drugs has been tested in large trials specifically for SFT, and the evidence comes mostly from small studies, so specialists encourage clinical trials for advanced disease. Because SFT is rare, care is best planned by a team experienced in sarcoma, including surgeons, pathologists, radiation oncologists and medical oncologists.
Many people, especially those whose tumor is in the chest and is completely removed, need no further treatment and do well over the long term. The outlook depends mostly on whether the tumor could be fully removed, where it was located and its risk features. Tumors deep in the abdomen, behind the abdominal lining or in the center of the chest tend to behave more aggressively, while those in the head and neck tend to grow more slowly. The defining feature of life after an SFT is long follow-up. The tumor can return or spread to other parts of the body, and this can happen more than ten years after surgery, even when the original tumor looked low risk. For that reason, specialists recommend regular imaging for many years, with the schedule tailored to each person's risk. Recovery from surgery itself depends on where the tumor was and how large the operation was. For people living with advanced SFT, the disease often progresses slowly compared with many other cancers, and treatment may continue in phases, switching between drugs as the tumor responds or grows.
Arrange a medical visit for a lasting cough, chest pain, shortness of breath or a new lump anywhere in the body that is growing. After treatment, keep scheduled scans and report new symptoms in the area of the original tumor or elsewhere, since a recurrence may be found earlier this way. Rarely, an SFT releases a hormone that drives blood sugar too low, a condition called Doege-Potter syndrome, which usually resolves once the tumor is removed. Contact your care team right away about episodes of shaking, sweating, dizziness or confusion, especially if you do not have diabetes, so that your blood sugar can be checked. During an episode, eat or drink something with sugar if you can do so safely. If someone passes out, has a seizure or is too confused to swallow safely, call 911.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with Solitary Fibrous Tumors is like, what's helped you, or ask the community a question.